Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

US11590117B2 · kind B2 · utility

Assignee

• CELGENE CORPORATION · US

Inventors

• Soraya Carrancio · San Diego, US
• Paul Hollenbach · Castro Valley, US
• Antonia Lopez-Girona · San Diego, US
• Kyle MacBeth · Boston, US
• Michael Pourdehnad · San Francisco, US
• Irit Rappley · San Diego, US
• Gang Lu · Nanhu, CN

Key dates

• Filing date: Jul 2, 2020
• Grant date: Feb 28, 2023
• Expiry date: Jul 2, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.